Geron Moves Low Dosage Arm To Optimal Dosage Level in IMbark Myelofibrosis Study.
Encouraging Trends Have Been Disclosed For Both IMbark (Myelofibrosis) and IMerge (MDS) Studies.
Likelihood of Breakthrough Therapy Designation Has Now Increased.
Geron's $130MM Cash Hoard and Low Burn Rate Make This a No-Brainer for Biotech Investors.
The Best News in This Early Look at Geron's Imetelstat Trials May Be That There Are No New Safety Concerns.
Geron Moves Low Dosage Arm To Optimal Dosage Level in IMbark Study
As I predicted in my previous article, Geron (NASDAQ:GERN) has moved the Imetelstat low dose 4.7mg/kg arm 1 of its IMbark Myelofibrosis Study to the optimal 9.4mg/kg dosage in arm2. Without rehashing all my points in my previous article, this sets the stage nicely for a more robust trial success possibly leading to breakthrough therapy designation for the drug. The 12-week review disclosed last week was solely intended to determine dosage adjustment or refinement in the study.
Encouraging Trends Have Been Disclosed For Both IMbark and IMerge Studies
Investors, however, were treated with an extra bit of positive news that got lost in the fog of analyst and stock pundit misinterpretation of the press release. Both the 9.4mg/kg arm 2 in the IMbark trial, as well as the IMerge/MDS trial are showing encouraging trends very early in the trial. As Anna Krassowska (Geron Investor Relations) indicated in an email to SA commenter "nosy" in response to his inquiry, "Note that clinical trials of other agents tested in myelofibrosis report data at 24 or 48 weeks and not 12.5."
Likelihood of Breakthrough Therapy Designation Has Now Increased
With the entire patient population in the IMbark trial now